Sign in Subscribe
Vaccines

Accelerated Development of COVID-19 Antibodies Breaks Traditions in Pharmaceutical Industry

Strategic Insights

— 1 min read

Astrazeneca's groundbreaking research on COVID-19 antibodies has sparked a new approach to vaccine development, allowing for unprecedentedly accelerated production timelines. By leveraging cutting-edge technology and agile workflows, the company expedited the process from discovery to global regulatory approvals in under six months, a feat that typically takes close to a decade. This achievement is attributed to the collaboration between AstraZeneca's research and manufacturing teams, who employed novel approaches to overcome traditional developmental challenges.

Key Takeaways:

  • AstraZeneca's AZD7442 (EVUSHELD) is a long-acting, SARS-CoV-2 spike receptor binding domain-specific neutralizing monoclonal antibody that was developed to target COVID-19.
  • The research team employed accelerated cell culture process development and characterization for cilgavimab and tixagevimab (AZD7442) in a contract manufacturing organization.
  • The process development and characterization were completed in less than six months, compared to the typical time frame of around 10 years.
  • The research used financial support from AstraZeneca to expedite the development of AZD7442.
  • The research was conducted in collaboration with multiple contributors, including Michael W. Handlogten, Stefanie Bosley, and Jie Zhu.

Statistics:

  • The development of AZD7442 (EVUSHELD) was expedited by adopting agile strategies that combined technological advances and highly accelerated workflows.
  • The research team completed the process development and characterization in less than six months, against the typical 10-year timeline.
  • AstraZeneca's hyper-accelerated antibody development process has opened new avenues for COVID-19 treatment and prevention.

Sources:

  • NewsRx. Reports Outline COVID-19 Findings from AstraZeneca [Accelerated Cell Culture Process Development and Characterization for Cilgavimab/tixagevimab (Azd7442) for the Prevention and Treatment of Covid-19]. Medical Letter on the CDC & FDA. September 14, 2025; p 181.
  • Biotechnology and Bioengineering. Accelerated Cell Culture Process Development and Characterization for Cilgavimab/tixagevimab (Azd7442) for the Prevention and Treatment of Covid-19. Vol. 122, No. 9. p. 2308-2318 (2025).

Read more